Welcome To The Critical Outcome Technologies Inc HUB On AGORACOM
Our disease Targets > Small cell lung cancer, Multiple sclerosis, HIV Integrase, Colorectal cancer & Adult acute leukemia
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM News Flash

AGORACOM WIRE - MONDAY MAY 28TH, 2012

SONOMAX completes $3 million equity financing

Caisse de dépôt et placement du Québec contributes a significant portion of financing

FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc. Read More   |   *SPONSOR

INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More

LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013  Read More   |   *SPONSOR

 

 

Close

Message: Announces Pilot Project Conclusion

Reply New Message
« Prev Message Back To Forum Go to Threaded View Next Message »
2nd shots 1 002
Clavis
Rank: [?]
President
Points: [?]
23987
Rating: [?]
Votes: 222 Score: 3.5
  • Currently 3.6/5 Stars.
Your Vote:
Please Log In to Vote
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

Announces Pilot Project Conclusion

posted on Aug 17, 09 04:57PM
August 17, 2009
Critical Outcome Technologies Inc. Announces Pilot Project Conclusion
LONDON, ONTARIO--(Marketwire - Aug. 17, 2009) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that COTI has received notification from Merck KGaA (FRANKFURT:MRK) of Darmstadt, Germany that it decided to discontinue the pursuit of compounds under the pilot project announced on October 17, 2007. The project called for COTI to identify drug discovery candidates for a specific oncology cellular target of importance to Merck KGaA.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS(R), which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development: small cell lung cancer, HIV integrase inhibitors, acute adult leukemia, multiple sclerosis, colorectal cancer and alzheimer's disease.

For further information, please visit the website at www.criticaloutcome.com.
Reply New Message
« Prev Message Back To Forum Go to Threaded View Next Message »

New Message

Please login to post a reply

Agoracom TV
Check out Agoracom's daily, fast-paced, newscast on the morning's top Small-Cap newsmakers
Featured News
Get top news releases from the Small-Cap world
Blog
Follow George Tsiolis's Small-Cap and Micro-Cap 2.0 Blog

Mesh With Us On The Web's Top Social Networking Sites

YouTube Facebook Twitter Picasa LinkedIn FriendFeed iTunes

Find Our Content Throughout The Web With Our New Media Partners

RIM AOL Yahoo ReportonBusiness

AGORACOM Quick Tips

Start A New HUB. Control. Quality. Refreshing. ... Start One Now
Click To Watch Today's Show

President's D.D.

New feature: Hub Presidents can add important links here.

Stock Quote

Open COT:CA Stock Quote

Investment Ideas

Like Critical Outcome Technologies Inc? Then you might also be interested in Star Navigation Systems Group Ltd.

Star Navigation Systems Group Ltd.
  • Developer of the TERRASTARTM in-flight safety monitoring system
  • The first system in the world to feature real-time in-flight data monitoring and diagnostics
  • echnical Partnership Agreement with Astrium, a wholly owned subsidiary of EADS

Hub Leaders

2nd shots 1 002
Clavis